Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 DIAGNOSED INCIDENT CASES OF ALL INVASIVE BREAST CANCER
5.2 AGE-SPECIFIC DIAGNOSED INCIDENT CASES OF ALL INVASIVE BREAST CANCER
5.3 TREATMENT RATE
5.4 MORTALITY RATE
5.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.6 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH OCBOLOGIST
6.8 INTERVIEWS WITH RESEARCHERS
6.9 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 CHEMOTHERAPY
11.2.1 TAXANES
11.2.1.1. BY DRUGS
11.2.1.1.1. PACLITAXEL
11.2.1.1.1.1 MARKET VALUE (USD MN)
11.2.1.1.1.2 MARKET VOLUME (IU)
11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.2. DOCETAXEL
11.2.1.1.2.1 MARKET VALUE (USD MN)
11.2.1.1.2.2 MARKET VOLUME (IU)
11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.3. ALBUMIN BOUND PACLITAXEL
11.2.1.1.3.1 MARKET VALUE (USD MN)
11.2.1.1.3.2 MARKET VOLUME (IU)
11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.4. OTHERS
11.2.1.2. BY DRUG TYPE
11.2.1.2.1. GENERICS
11.2.1.2.1.1 MARKET VALUE (USD MN)
11.2.1.2.1.2 MARKET VOLUME (IU)
11.2.1.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.1.2.2. BRANDED
11.2.1.2.2.1 MARKET VALUE (USD MN)
11.2.1.2.2.2 MARKET VOLUME (IU)
11.2.1.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.2 ANTHRACYCLINES
11.2.2.1. BY TYPE
11.2.2.1.1. DOXORUBICIN
11.2.2.1.1.1 MARKET VALUE (USD MN)
11.2.2.1.1.2 MARKET VOLUME (IU)
11.2.2.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.2. LIPOSOMAL DOXORUBICIN
11.2.2.1.2.1 MARKET VALUE (USD MN)
11.2.2.1.2.2 MARKET VOLUME (IU)
11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.3. EPIRUBICIN
11.2.2.1.3.1 MARKET VALUE (USD MN)
11.2.2.1.3.2 MARKET VOLUME (IU)
11.2.2.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.2.1.4. OTHERS
11.2.2.2. BY DRUG TYPE
11.2.2.2.1. GENERICS
11.2.2.2.1.1 MARKET VALUE (USD MN)
11.2.2.2.1.2 MARKET VOLUME (IU)
11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.2. BRANDED
11.2.2.2.2.1 MARKET VALUE (USD MN)
11.2.2.2.2.2 MARKET VOLUME (IU)
11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.3 PLATINUM AGENTS
11.2.3.1. BY TYPE
11.2.3.1.1. CISPLATIN
11.2.3.1.1.1 MARKET VALUE (USD MN)
11.2.3.1.1.2 MARKET VOLUME (IU)
11.2.3.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.2. CARBOPLATIN
11.2.3.1.2.1 MARKET VALUE (USD MN)
11.2.3.1.2.2 MARKET VOLUME (IU)
11.2.3.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.3.1.3. OTHERS
11.2.3.2. BY DRUG TYPE
11.2.3.2.1. GENERICS
11.2.3.2.1.1 MARKET VALUE (USD MN)
11.2.3.2.1.2 MARKET VOLUME (IU)
11.2.3.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.3.2.2. BRANDED
11.2.3.2.2.1 MARKET VALUE (USD MN)
11.2.3.2.2.2 MARKET VOLUME (IU)
11.2.3.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.4 ANTIMETABOLITES
11.2.4.1. BY TYPE
11.2.4.1.1. CAPECITABINE
11.2.4.1.1.1 MARKET VALUE (USD MN)
11.2.4.1.1.2 MARKET VOLUME (IU)
11.2.4.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.4.1.2. GEMCITABINE
11.2.4.1.2.1 MARKET VALUE (USD MN)
11.2.4.1.2.2 MARKET VOLUME (IU)
11.2.4.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.4.2. BY DRUG TYPE
11.2.4.2.1. GENERICS
11.2.4.2.1.1 MARKET VALUE (USD MN)
11.2.4.2.1.2 MARKET VOLUME (IU)
11.2.4.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.4.2.2. BRANDED
11.2.4.2.2.1 MARKET VALUE (USD MN)
11.2.4.2.2.2 MARKET VOLUME (IU)
11.2.4.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.5 MICROTUBULE INHIBITORS
11.2.5.1. BY TYPE
11.2.5.1.1. IXABEPILONE
11.2.5.1.1.1 MARKET VALUE (USD MN)
11.2.5.1.1.2 MARKET VOLUME (IU)
11.2.5.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.2. ERBULIN
11.2.5.1.2.1 MARKET VALUE (USD MN)
11.2.5.1.2.2 MARKET VOLUME (IU)
11.2.5.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.3. OTHERS
11.2.5.2. BY DRUG TYPE
11.2.5.2.1. GENERICS
11.2.5.2.1.1 MARKET VALUE (USD MN)
11.2.5.2.1.2 MARKET VOLUME (IU)
11.2.5.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.5.2.2. BRANDED
11.2.5.2.2.1 MARKET VALUE (USD MN)
11.2.5.2.2.2 MARKET VOLUME (IU)
11.2.5.2.2.3 AVERAGE SELLING PRICE (USD)
11.3 TARGETED DRUG THERAPY
11.3.1 MONOCLONAL ANTIBODIES
11.3.1.1. BY TYPE
11.3.1.1.1. TRASTUZUMAB
11.3.1.1.1.1 MARKET VALUE (USD MN)
11.3.1.1.1.2 MARKET VOLUME (IU)
11.3.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.2. PERTUZUMAB
11.3.1.1.2.1 MARKET VALUE (USD MN)
11.3.1.1.2.2 MARKET VOLUME (IU)
11.3.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.3. TRASTUZUMAB, PERTUZUMAB, AND HYALURONIDASE INJECTION (COMBINATION DRUGS)
11.3.1.1.3.1 MARKET VALUE (USD MN)
11.3.1.1.3.2 MARKET VOLUME (IU)
11.3.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.4. MARGETUXIMAB
11.3.1.1.4.1 MARKET VALUE (USD MN)
11.3.1.1.4.2 MARKET VOLUME (IU)
11.3.1.1.4.3 AVERAGE SELLING PRICE (USD)
11.3.1.1.5. OTHERS
11.3.1.2. BY DRUG TYPE
11.3.1.2.1. BIOLOGICS
11.3.1.2.1.1 MARKET VALUE (USD MN)
11.3.1.2.1.2 MARKET VOLUME (IU)
11.3.1.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.1.2.2. BIOSIMILAR
11.3.1.2.2.1 MARKET VALUE (USD MN)
11.3.1.2.2.2 MARKET VOLUME (IU)
11.3.1.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.2 KINASE INHIBITORS
11.3.2.1. BY TYPE
11.3.2.1.1. TUCATINIB
11.3.2.1.1.1 MARKET VALUE (USD MN)
11.3.2.1.1.2 MARKET VOLUME (IU)
11.3.2.1.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.1.2. LAPATINIB
11.3.2.1.2.1 MARKET VALUE (USD MN)
11.3.2.1.2.2 MARKET VOLUME (IU)
11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.1.3. NERTINIB
11.3.2.1.3.1 MARKET VALUE (USD MN)
11.3.2.1.3.2 MARKET VOLUME (IU)
11.3.2.1.3.3 AVERAGE SELLING PRICE (USD)
11.3.2.2. BY DRUG TYPE
11.3.2.2.1. GENERICS
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (IU)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. BRANDED
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (IU)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.3 ANTIBODY DRUG CONJUGATES
11.3.3.1. ADO-TRASTUZUMAB EMTANSINE
11.3.3.1.1. MARKET VALUE (USD MN)
11.3.3.1.2. MARKET VOLUME (IU)
11.3.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.3.2. FAM-TRASTUZUMAB DERUXTECAN
11.3.3.2.1. MARKET VALUE (USD MN)
11.3.3.2.2. MARKET VOLUME (IU)
11.3.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.3.3. OTHERS
11.4 HORMONE THERAPY
11.4.1 BY TYPE
11.4.1.1. TAMOXIFEN
11.4.1.1.1. MARKET VALUE (USD MN)
11.4.1.1.2. MARKET VOLUME (IU)
11.4.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.2. TOREMIFENE
11.4.1.2.1. MARKET VALUE (USD MN)
11.4.1.2.2. MARKET VOLUME (IU)
11.4.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3. FULVESTRANT
11.4.1.3.1. MARKET VALUE (USD MN)
11.4.1.3.2. MARKET VOLUME (IU)
11.4.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.4. OTHERS
11.4.2 BY DRUG TYPE
11.4.2.1. GENERICS
11.4.2.1.1. MARKET VALUE (USD MN)
11.4.2.1.2. MARKET VOLUME (IU)
11.4.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.2.2. BRANDED
11.4.2.2.1. MARKET VALUE (USD MN)
11.4.2.2.2. MARKET VOLUME (IU)
11.4.2.2.3. AVERAGE SELLING PRICE (USD)
11.5 OTHERS
11.5.1 RADIATION THERAPY
11.5.2 SURGERY
11.5.3 RECONSTRUCTIVE SURGERY
12 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY USAGE TYPE
12.1 NEOADJUVENT USE
12.2 ADJUVANT USE
13 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY STAGES
13.1 STAGE 0
13.2 STAGE I
13.3 STAGE II
13.4 STAGE III
13.5 STAGE IV
14 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 BELOW 30 YEARS
14.3 30-50 YEARS
14.4 ABOVE 50 YEARS
15 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.3 PARENTERAL
15.4 OTHERS
16 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 ACADEMIC AND RESEARCH INSTITUTES
16.5 OTHERS
17 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 HOSPITAL PHARMACY
17.3 RETAIL PHARMACY
17.4 ONLINE PHARMACY
17.5 OTHERS
18 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY GEOGRAPHY
18.1 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.2 NORTH AMERICA
18.2.1 U.S.
18.2.1.1. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY TREATMENT
18.2.1.2. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY USAGE TYPE
18.2.1.3. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY STAGES
18.2.1.4. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY AGE GROUP
18.2.1.5. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
18.2.1.6. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY END USER
18.2.1.7. U.S. HER2 POSITIVE BREAST CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.2.1.8. CANADA
18.2.1.9. MEXICO
18.2.2 EUROPE
18.2.2.1. GERMANY
18.2.2.2. FRANCE
18.2.2.3. U.K.
18.2.2.4. ITALY
18.2.2.5. SPAIN
18.2.2.6. RUSSIA
18.2.2.7. TURKEY
18.2.2.8. BELGIUM
18.2.2.9. DENMARK
18.2.2.10. SWEDEN
18.2.2.11. POLAND
18.2.2.12. NORWAY
18.2.2.13. FINLAND
18.2.2.14. NETHERLANDS
18.2.2.15. SWITZERLAND
18.2.2.16. REST OF EUROPE
18.2.3 ASIA-PACIFIC
18.2.3.1. JAPAN
18.2.3.2. CHINA
18.2.3.3. SOUTH KOREA
18.2.3.4. INDIA
18.2.3.5. AUSTRALIA
18.2.3.6. SINGAPORE
18.2.3.7. THAILAND
18.2.3.8. MALAYSIA
18.2.3.9. INDONESIA
18.2.3.10. PHILIPPINES
18.2.3.11. TAIWAN
18.2.3.12. INDONESIA
18.2.3.13. VIETNAM
18.2.3.14. REST OF ASIA-PACIFIC
18.2.4 SOUTH AMERICA
18.2.4.1. BRAZIL
18.2.4.2. ARGENTINA
18.2.4.3. REST OF SOUTH AMERICA
18.2.5 MIDDLE EAST AND AFRICA
18.2.5.1. SOUTH AFRICA
18.2.5.2. SAUDI ARABIA
18.2.5.3. UAE
18.2.5.4. EGYPT
18.2.5.5. BAHRAIN
18.2.5.6. KUWAIT
18.2.5.7. QATAR
18.2.5.8. OMAN
18.2.5.9. ISRAEL
18.2.5.10. REST OF MIDDLE EAST AND AFRICA
19 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20.5 MERGERS & ACQUISITIONS
20.6 NEW PRODUCT DEVELOPMENT & APPROVALS
20.7 EXPANSIONS
20.8 REGULATORY CHANGES
20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
21 GLOBAL HER2 POSITIVE BREAST CANCER TREATMENT MARKET, COMPANY PROFILE
21.1 ASTRAZENCA
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 DAIICHI SANKYO
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 BRISTOL MEYERS SQUIBB
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 EISAI INC
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 F-HOFFMANN LA ROCHE
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 GSK
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 GENETECH
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
21.8 PFIZER
21.8.1 COMPANY OVERVIEW
21.8.2 REVENUE ANALYSIS
21.8.3 GEOGRAPHIC PRESENCE
21.8.4 PRODUCT PORTFOLIO
21.8.5 RECENT DEVELOPMENTS
21.9 MERCK & CO, INC
21.9.1 COMPANY OVERVIEW
21.9.2 REVENUE ANALYSIS
21.9.3 GEOGRAPHIC PRESENCE
21.9.4 PRODUCT PORTFOLIO
21.9.5 RECENT DEVELOPMENTS
21.1 PUMA BIOTECHNOLOGY INC
21.10.1 COMPANY OVERVIEW
21.10.2 REVENUE ANALYSIS
21.10.3 GEOGRAPHIC PRESENCE
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENTS
21.11 ELI LILLY
21.11.1 COMPANY OVERVIEW
21.11.2 REVENUE ANALYSIS
21.11.3 GEOGRAPHIC PRESENCE
21.11.4 PRODUCT PORTFOLIO
21.11.5 RECENT DEVELOPMENTS
21.12 CELLTRION
21.12.1 COMPANY OVERVIEW
21.12.2 REVENUE ANALYSIS
21.12.3 GEOGRAPHIC PRESENCE
21.12.4 PRODUCT PORTFOLIO
21.12.5 RECENT DEVELOPMENTS
21.13 GILEAD SVIENCES
21.13.1 COMPANY OVERVIEW
21.13.2 REVENUE ANALYSIS
21.13.3 GEOGRAPHIC PRESENCE
21.13.4 PRODUCT PORTFOLIO
21.13.5 RECENT DEVELOPMENTS
21.14 AMGEN
21.14.1 COMPANY OVERVIEW
21.14.2 REVENUE ANALYSIS
21.14.3 GEOGRAPHIC PRESENCE
21.14.4 PRODUCT PORTFOLIO
21.14.5 RECENT DEVELOPMENTS
21.15 DR REDDY LABORATORIES
21.15.1 COMPANY OVERVIEW
21.15.2 REVENUE ANALYSIS
21.15.3 GEOGRAPHIC PRESENCE
21.15.4 PRODUCT PORTFOLIO
21.15.5 RECENT DEVELOPMENTS
21.16 MYLAN PHARMACEUTICALS
21.16.1 COMPANY OVERVIEW
21.16.2 REVENUE ANALYSIS
21.16.3 GEOGRAPHIC PRESENCE
21.16.4 PRODUCT PORTFOLIO
21.16.5 RECENT DEVELOPMENTS
21.17 KYOWA KRIN INTERNATIONAL
21.17.1 COMPANY OVERVIEW
21.17.2 REVENUE ANALYSIS
21.17.3 GEOGRAPHIC PRESENCE
21.17.4 PRODUCT PORTFOLIO
21.17.5 RECENT DEVELOPMENTS
21.18 JOHNSONS & JOHNSON (JANSSEN PHARMACEUTICASL)
21.18.1 COMPANY OVERVIEW
21.18.2 REVENUE ANALYSIS
21.18.3 GEOGRAPHIC PRESENCE
21.18.4 PRODUCT PORTFOLIO
21.18.5 RECENT DEVELOPMENTS
21.19 BAXTER HEALTHCARE
21.19.1 COMPANY OVERVIEW
21.19.2 REVENUE ANALYSIS
21.19.3 GEOGRAPHIC PRESENCE
21.19.4 PRODUCT PORTFOLIO
21.19.5 RECENT DEVELOPMENTS
21.2 AMNEAL PHARMACEUTICALS
21.20.1 COMPANY OVERVIEW
21.20.2 REVENUE ANALYSIS
21.20.3 GEOGRAPHIC PRESENCE
21.20.4 PRODUCT PORTFOLIO
21.20.5 RECENT DEVELOPMENTS
21.21 ABBOTT LABORATORIES
21.21.1 COMPANY OVERVIEW
21.21.2 REVENUE ANALYSIS
21.21.3 GEOGRAPHIC PRESENCE
21.21.4 PRODUCT PORTFOLIO
21.21.5 RECENT DEVELOPMENTS
21.22 ABBVIE INC
21.22.1 COMPANY OVERVIEW
21.22.2 REVENUE ANALYSIS
21.22.3 GEOGRAPHIC PRESENCE
21.22.4 PRODUCT PORTFOLIO
21.22.5 RECENT DEVELOPMENTS
21.23 NOVARTIS AG
21.23.1 COMPANY OVERVIEW
21.23.2 REVENUE ANALYSIS
21.23.3 GEOGRAPHIC PRESENCE
21.23.4 PRODUCT PORTFOLIO
21.23.5 RECENT DEVELOPMENTS
21.24 TEVA PHARMACEUTICALS
21.24.1 COMPANY OVERVIEW
21.24.2 REVENUE ANALYSIS
21.24.3 GEOGRAPHIC PRESENCE
21.24.4 PRODUCT PORTFOLIO
21.24.5 RECENT DEVELOPMENTS
21.25 APOTEX CORPORATION
21.25.1 COMPANY OVERVIEW
21.25.2 REVENUE ANALYSIS
21.25.3 GEOGRAPHIC PRESENCE
21.25.4 PRODUCT PORTFOLIO
21.25.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
22 RELATED REPORTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
